Related Experiment Video
Updated: Jul 20, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Clinical studies with ropinirole in Parkinson's disease and RLS
Wolfgang H Jost1, Dieter Angersbach, Olivier Rascol
1Dept. Neurology, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191, Wiesbaden, Germany. jost.neuro@dkd-wiesbaden.de
Abstract:
Ropinirole is a modern dopamine agonist with a half-life of medium extent that is highly selective for D(2)-receptors. Ropinirole is an indole derivative and thus does not belong to the group of ergoline dopamine receptor agonists. Its effect has been proved in a number of controlled studies in both monotherapy and combination treatments of Parkinson's disease. We can meanwhile refer to the long-term data of studies that have been run for more than 10 years. The substance has also been approved for the management of restless legs syndrome. A long-acting formula of the substance will be available soon.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Alterations in Muscle Tone lll
Restless Leg Syndrome and Night Terrors
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
